Shelton Capital Management’s Amedisys AMED Stock Holding History

Shelton Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,813	Closed	-$312K	–	719
2022 Q1	$312K	Hold	1,813	–	–	0.01%	528
2021 Q4	$293K	Hold	1,813	–	–	0.01%	572
2021 Q3	$270K	Hold	1,813	–	–	0.01%	608
2021 Q2	$444K	Hold	1,813	–	–	0.02%	406
2021 Q1	$480K	Hold	1,813	–	–	0.02%	400
2020 Q4	$532K	Sell	1,813 -66	-4%	-$16.9K	0.02%	335
2020 Q3	$444K	Hold	1,879	–	–	0.02%	453
2020 Q2	$373K	Sell	1,879 -97	-5%	-$18.1K	0.02%	380
2020 Q1	$363K	Hold	1,976	–	–	0.03%	349
2019 Q4	$330K	Hold	1,976	–	–	0.02%	483
2019 Q3	$259K	Hold	1,976	–	–	0.02%	603
2019 Q2	$240K	Buy	+1,976	New	+$234K	0.01%	671
2019 Q1	–	Sell	-2,871	Closed	-$336K	–	834
2018 Q4	$336K	Hold	2,871	–	–	0.02%	426
2018 Q3	$359K	Buy	2,871 +100	+4%	+$11K	0.02%	497
2018 Q2	$237K	Buy	+2,771	New	+$203K	0.01%	707

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Shelton Capital Management's AMED Position: Q2 2022 in Review

Shelton Capital Management sold out of Amedisys (AMED) in Q2 2022, closing a stake of 1,813 shares — an estimated $312K sold.

Shelton Capital Management first reported a position in AMED in Q2 2018 and held it in 15 quarters. The position peaked at $532K in Q4 2020. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

Shelton Capital Management reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
Shelton Capital Management sold 1,813 Amedisys shares in Q2 2022, an estimated $312K.
Shelton Capital Management first reported a position in Amedisys in Q2 2018 and held it in 15 quarters.
Shelton Capital Management's Amedisys position peaked at $532K in Q4 2020.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Shelton Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.